4-Methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer
Hyaluronan (HA) is a prominent component of the extracellular matrix (ECM) at many sites of chronic inflammation, including type 1 diabetes (T1D), multiple sclerosis (MS), and numerous malignancies. Recent publications have demonstrated that when HA synthesis is inhibited using 4-methylumbelliferone...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2015-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fimmu.2015.00123/full |
| _version_ | 1831737468223750144 |
|---|---|
| author | Nadine eNagy Hedwich F. Kuipers Adam R. Frymoyer Heather D. Ishak Jennifer B. Bollyky Thomas N. Wight Paul L. Bollyky |
| author_facet | Nadine eNagy Hedwich F. Kuipers Adam R. Frymoyer Heather D. Ishak Jennifer B. Bollyky Thomas N. Wight Paul L. Bollyky |
| author_sort | Nadine eNagy |
| collection | DOAJ |
| description | Hyaluronan (HA) is a prominent component of the extracellular matrix (ECM) at many sites of chronic inflammation, including type 1 diabetes (T1D), multiple sclerosis (MS), and numerous malignancies. Recent publications have demonstrated that when HA synthesis is inhibited using 4-methylumbelliferone (4-MU) beneficial effects are observed in several animal models of these diseases. Notably, 4-MU is an already approved drug in Europe and Asia called hymecromone where it is used to treat biliary spasm. However, there is uncertainty regarding how 4-MU treatment provides benefit in these animal models and the potential long-term consequences of HA inhibition. Here, we review what is known about how HA contributes to immune dysregulation and tumor progression. Then, we review what is known about 4-MU and hymecromone in terms of mechanism of action, pharmacokinetics, and safety. Finally, we review recent studies detailing the use of 4-MU to treat animal models of cancer and autoimmunity. |
| first_indexed | 2024-12-21T13:03:17Z |
| format | Article |
| id | doaj.art-f596bbda5b5c44baa8b4932f0b2a6eaa |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-21T13:03:17Z |
| publishDate | 2015-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-f596bbda5b5c44baa8b4932f0b2a6eaa2022-12-21T19:03:06ZengFrontiers Media S.A.Frontiers in Immunology1664-32242015-03-01610.3389/fimmu.2015.001231342384-Methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancerNadine eNagy0Hedwich F. Kuipers1Adam R. Frymoyer2Heather D. Ishak3Jennifer B. Bollyky4Thomas N. Wight5Paul L. Bollyky6Stanford University School of MedicineStanford University School of MedicineStanford University School of MedicineStanford University School of MedicineStanford University School of MedicineBenaroya Research InstituteStanford University School of MedicineHyaluronan (HA) is a prominent component of the extracellular matrix (ECM) at many sites of chronic inflammation, including type 1 diabetes (T1D), multiple sclerosis (MS), and numerous malignancies. Recent publications have demonstrated that when HA synthesis is inhibited using 4-methylumbelliferone (4-MU) beneficial effects are observed in several animal models of these diseases. Notably, 4-MU is an already approved drug in Europe and Asia called hymecromone where it is used to treat biliary spasm. However, there is uncertainty regarding how 4-MU treatment provides benefit in these animal models and the potential long-term consequences of HA inhibition. Here, we review what is known about how HA contributes to immune dysregulation and tumor progression. Then, we review what is known about 4-MU and hymecromone in terms of mechanism of action, pharmacokinetics, and safety. Finally, we review recent studies detailing the use of 4-MU to treat animal models of cancer and autoimmunity.http://journal.frontiersin.org/Journal/10.3389/fimmu.2015.00123/fullHymecromoneCancerhyaluronan4-MethylumbelliferoneImmune diseases |
| spellingShingle | Nadine eNagy Hedwich F. Kuipers Adam R. Frymoyer Heather D. Ishak Jennifer B. Bollyky Thomas N. Wight Paul L. Bollyky 4-Methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer Frontiers in Immunology Hymecromone Cancer hyaluronan 4-Methylumbelliferone Immune diseases |
| title | 4-Methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer |
| title_full | 4-Methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer |
| title_fullStr | 4-Methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer |
| title_full_unstemmed | 4-Methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer |
| title_short | 4-Methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer |
| title_sort | 4 methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation autoimmunity and cancer |
| topic | Hymecromone Cancer hyaluronan 4-Methylumbelliferone Immune diseases |
| url | http://journal.frontiersin.org/Journal/10.3389/fimmu.2015.00123/full |
| work_keys_str_mv | AT nadineenagy 4methylumbelliferonetreatmentandhyaluronaninhibitionasatherapeuticstrategyininflammationautoimmunityandcancer AT hedwichfkuipers 4methylumbelliferonetreatmentandhyaluronaninhibitionasatherapeuticstrategyininflammationautoimmunityandcancer AT adamrfrymoyer 4methylumbelliferonetreatmentandhyaluronaninhibitionasatherapeuticstrategyininflammationautoimmunityandcancer AT heatherdishak 4methylumbelliferonetreatmentandhyaluronaninhibitionasatherapeuticstrategyininflammationautoimmunityandcancer AT jenniferbbollyky 4methylumbelliferonetreatmentandhyaluronaninhibitionasatherapeuticstrategyininflammationautoimmunityandcancer AT thomasnwight 4methylumbelliferonetreatmentandhyaluronaninhibitionasatherapeuticstrategyininflammationautoimmunityandcancer AT paullbollyky 4methylumbelliferonetreatmentandhyaluronaninhibitionasatherapeuticstrategyininflammationautoimmunityandcancer |